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ABSTRACT
Efficacious treatments for winter seasonal affective disorder (SAD) include light
therapy (LT) and cognitive-behavioral therapy (CBT-SAD); however, it is unknown
whether patient baseline characteristics differentially predict treatment outcomes. The
present study investigated body mass index (BMI) and atypical balance as prognostic and
prescriptive predictors of SAD treatment outcomes using data from a parent study in
which 177 adults diagnosed with Major Depression, Recurrent with Seasonal Pattern
were randomized to either CBT-SAD (n = 88) or LT (n = 89). At pre-treatment, BMI
was assessed and atypical balance was derived using the Structured Interview Guide for
the Hamilton Rating Scale for Depression–Seasonal Affective Disorder Version (SIGHSAD). Hierarchical linear and logistic regressions were used to investigate the main
effects of treatment type, BMI, and atypical balance score and their interactive effects on
SIGH-SAD depression outcomes at post-treatment and first and second winter follow-up.
Linear mixed modeling was used to examine the effect of BMI and atypical balance on
the rate of SIGH-SAD symptom improvement during the treatment period. BMI x
treatment group interaction significantly predicted depression remission at second winter
follow-up such that at BMI < 26.1, the probability of depression remission was higher
with CBT-SAD than LT. The atypical balance x treatment group interaction significantly
predicted depression remission at second winter followup such that the probability of
depression remission was higher with CBT-SAD than LT at atypical balance < 40.3%.
The linear mixed model analyses uncovered a significant interaction between time, BMI,
and treatment group, indicating the rate of change in SIGH-SAD scores was slower in LT
and faster in CBT-SAD as BMI increased. Taken together, results suggest that BMI and
atypical balance are predictors of depression treatment outcomes, and thus may be useful
in clinical decision making and efforts for precision medicine.

ACKNOWLEDGMENTS
I am deeply thankful for all the support I have received while on this journey!
Educational degrees are not earned in isolation, and mine has definitely been a
collective effort. Much love to my mom, my brothers, Khudejha Asghar, Tina
Cerin, Pannu Khin, and Jess Perez for their unending emotional support. I am
grateful for my advisor, Kelly Rohan, as well as Mike DeSarno, and Teo
Postolache, for all the wisdom and guidance they have offered for this project. I
am thankful for those who came before me and for my parents, who were brave
enough to cross oceans in the hopes of a brighter future for their children.
Gratitude abounds to God and the universe for charting my path, to the ancestors
in my lineage for ordering my steps, and to the intuition I am learning to listen to
more intently. Thank you.

ii

TABLE OF CONTENTS

Page

LIST OF TABLES ....................................................................................................... iv

LIST OF FIGURES .......................................................................................................v

CHAPTER 1: INTRODUCTION ..................................................................................1

CHAPTER 2: METHOD ...............................................................................................7

CHAPTER 3: RESULTS .............................................................................................11

CHAPTER 4: DISCUSSION.......................................................................................23

REFERENCES ............................................................................................................39

iii

LIST OF TABLES
Table

Page

Table 1. Descriptive statistics for predictor variables and baseline medical
comorbidities……………………………..………...…..………………..…….…………....30
Table 2. Bivariate correlations between predictor and outcome variables……………..31
Table 3. Regression analyses predicting depression scores………………………….....32
Table 4. Regression analyses predicting depression remission………………………....33
Table 5. Regression analyses predicting depression recurrence... ……………………..34
Table 6. Linear mixed models predicting depression post-treatment scores………..……35

iv

LIST OF FIGURES
Figure

Page

Figure 1. The effect of BMI on the probability of SIGH-SAD remission at Winter 2
by treatment group after adjusting for pretreatment SIGH-SAD score……………………36
Figure 2. The effect of pre-treatment atypical balance on probability of SIGH-SAD
remission at Winter 2 by treatment group after adjusting for pre-treatment
SIGH-SAD score…………………………………………………………………………37
Figure 3. The marginal effects of centered BMI on change in SIGH-SAD score by
treatment group…………………………………………………………………………..38

v

CHAPTER 1: INTRODUCTION
Winter seasonal affective disorder (SAD) is a form of major depression
characterized by the onset of depression symptoms in the fall and winter seasons that
remit in the spring and summer. Although light therapy (LT) is the most long-standing
treatment for this disorder, cognitive-behavioral therapy tailored to SAD (CBT-SAD;
Rohan, 2008) is also an effective treatment. Rohan and colleagues conducted a
randomized clinical trial comparing LT and CBT-SAD in 177 adult SAD patients. LT
and CBT-SAD showed comparable improvements in depression and very similar
remission rates at post-treatment (47.2% vs. 47.6%, respectively; Rohan et al., 2015);
however, CBT-SAD was associated with less severe depressive symptoms and fewer
depression recurrences two winters following treatment (27.3% vs. 45.6%; Rohan et al.,
2016). These findings align with those of prior studies supporting CBT-SAD’s
superiority over LT on long-term outcomes (Rohan, Roecklein, Lacy et al., 2009).
When there are multiple effective treatments for a condition, it is imperative to
understand which treatment may work best for specific individuals, as this can maximize
positive treatment outcomes and improve healthcare cost-effectiveness. This process,
called “precision medicine,” involves elucidating both prognostic and prescriptive
factors. Prognostic factors are predictive of treatment outcome, regardless of treatment
type (i.e., the presence of a statistically significant main effect), whereas prescriptive
factors are predictive of which treatment has better outcomes for a given patient profile
(i.e., a moderator indicated by the presence of a statistically significant predictor ×
treatment interaction).
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Much research has been dedicated to exploring baseline factors that impact
treatment outcomes for Major Depressive Disorder. There is increasing interest in the
examination of Body Mass Index (BMI) – a measure of body fat determined by weight
and height – as a potential predictor of treatment outcomes for depression. This metric is
inexpensive, easy-to-use, and commonly assessed in healthcare settings. Although not a
diagnostic tool or independently indicative of individual health, BMI is strongly
associated with cardiovascular disease (Global Burden of Disease 2015 Obesity
Collaborators, 2017), Type II Diabetes (Holmes et al., 2014), and mortality (Aune et al.,
2016). BMI categories are classified according to increasing health risk (Table 1) and are
applicable for non-pregnant individuals 18 years of age or older.
Studies focusing on BMI as a predictor of treatment outcomes with antidepressant
medications have produced mixed findings. For example, Toups et al. (2013) examined
BMI as a moderator of depression response and remission for individuals with chronic or
recurrent Major Depressive Disorder (MDD), and found no difference in outcome across
BMI categories at 12-weeks (post-treatment) with escitalopram, bupropion, venlafaxine,
mirtazapine, or a combination of these antidepressants. Similarly, a study exploring the
association between the components of metabolic syndrome and treatment resistance to
antidepressants found no relationship between high BMI (< 27.5 kg/m2) and treatmentresistant depression (Sagud et al., 2013). On the other hand, several studies indicate an
association between higher BMI and poor response to antidepressant medications. For
example, a meta-analysis of three clinical trials of MDD patients treated with SSRIs or
SNRIs found that individuals within the normal BMI range showed a better
antidepressant response than those who were overweight or obese based on BMI
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(Oskooilar et al., 2009). Further, in a study of sustained remission among participants
with depressive disorders, Dennehy and colleagues (2015) found non-remitters had a
higher average BMI and an increased likelihood of BMI-defined obesity when compared
to remitters.
More current work extends this line of research by examining remission
outcomes according to antidepressant combination and type. Green and colleagues (2017)
found BMI differentially predicted remission according to antidepressant type.
Specifically, morbidly obese patients were more likely to remit on venlafaxine-XR than
those in the normal BMI range. In a different study (Jha et al., 2018), BMI differentially
predicted antidepressant treatment outcomes, whereby normal-weight and underweight
participants were less likely remit when treated with a bupropion-SSRI combination
relative to SSRI-monotherapy. However, obese class II participants were more likely to
experience remission when treated with the bupropion-SSRI combination than SSRImonotherapy. These studies highlight the potential utility of BMI as a tool to aid clinical
decision making regarding personalized treatment for depression, particularly when
multiple efficacious treatments are available. Currently, we are not aware of any studies
that have examined BMI as a prognostic or prescriptive factor in CBT for depression.
Investigating BMI as a predictor of CBT for depression outcomes is critical, as this
characteristic may aid in treatment decision-making.
There are several factors that may explain the inconsistent findings regarding
BMI and depression treatment outcomes. Some researchers postulate that atypical
depressive symptoms contribute to the heterogeneity of depressive profiles and, therefore,
to treatment outcomes. Atypical depressive symptoms include significant weight gain,
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increase in appetite, hypersomnia, and leaden paralysis (i.e., the feeling that one’s limbs
are weighed down; Lojko et al., 2015). Individuals with a higher proportion of atypical
symptoms are more likely to have obesity-related health issues and increased levels of
inflammatory markers (Lamers et al., 2013; Woo et al., 2016). As such, understanding
the impact of excess bodyweight on atypical depressive symptoms may better clarify the
relationship between body weight and antidepressant treatment outcomes. Toups et al.
(2013) found that atypical features were more common among high-BMI participants,
and melancholic features were more common among low-BMI participants. In this
sample, increasing BMI was significantly associated with both higher atypical features
and lower melancholic features. Furthermore, in a prospective population study of MDD
subtypes and changes in adiposity, Lasserre and colleagues (2014) reported a significant
association between MDD with atypical features and increased BMI over a 5.5-year
period not explained by confounders (e.g., comorbid mental health disorders,
sociodemographic or lifestyle traits, antidepressants, or weight-increasing medications).
Taken together, this information suggests that BMI and atypical symptoms may interact
in important ways that impact depression treatment outcomes.
Despite the literature examining BMI as a predictor of nonseasonal MDD
treatment outcomes, the research examining BMI as a predictor of treatment outcomes
for specific subtypes of MDD – such as SAD – is quite limited. SAD is a particularly
useful depression subtype to examine with respect to BMI, as SAD depressive episodes
are recurrent and characterized by atypical symptoms (e.g., hypersomnia, increased
appetite and food intake, carbohydrate cravings, heaviness in limbs, decreased energy).
To our knowledge, only one published study (Dimitrova et al., 2017) investigated BMI as
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a predictor of SAD treatment outcomes. Higher BMI emerged as a positive prognostic
indicator for LT treatment outcomes, such that SAD patients with higher BMIs showed a
larger reduction in scores on the Structured Interview Guide for the Hamilton Depression
Rating Scale – Seasonal Affective Disorder version (SIGH-SAD) after six weeks of LT
relative to those with lower BMIs (Dimitrova et al., 2017). Further, baseline atypical
balance score, operationalized as (8-item atypical subscale score/total SIGH-SAD score)
×100, significantly predicted LT outcomes, such that individuals with higher atypical
balance showed greater improvement with LT.
Dimitrova and colleagues’ (2017) findings highlight higher BMI and a larger
proportion of atypical symptoms in presenting symptoms as positive prognostic
indicators of LT outcomes for SAD. The present study used data from Rohan et al.’s
(2015, 2016) parent randomized clinical trial comparing LT to CBT-SAD to investigate
BMI and atypical balance score as 1) prognostic and prescriptive predictors of acute and
long-term SAD treatment outcomes and 2) predictors of rate of symptom improvement
during treatment.
This project extends Dimitrova and colleagues’ research in several ways. First,
the parent trial includes a comparator treatment – CBT-SAD – that has demonstrated
effectiveness in treating SAD (Rohan et al., 2015, 2016), allowing for examination of
BMI and atypical balance as prescriptive factors to inform which treatment may prove
more effective for specific individuals. Second, the parent study evaluated outcomes at
treatment endpoint as well as at first and second winter follow-ups, allowing for an
evaluation of the predictive ability of BMI and atypical balance with regard to longer
term outcomes beyond treatment endpoint. Third, the project investigated BMI and
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atypical balance score as predictors of the rate of improvement during treatment, thus
extending scientific knowledge of the relationship between these constructs. Fourth, in
addition to examining continuous depression scores as outcomes, the project adds to
Dimitrova and colleagues’ (2017) work by evaluating BMI and atypical balance as
predictors of two clinically meaningful dichotomous outcomes: depression remission and
(at follow-ups) recurrence. The public health burden of depression largely stems from the
fact that it is recurring, and costly to both the individual and society. Therefore, the
ability to predict remission or recurrence is useful for determining which treatment may
be more long-lasting for a specific patient profile.
We view this work as exploratory given that there is only one prior study like this
one using SAD patients (Dimitrova et al., 2017). Based on that study, we hypothesized
that pre-treatment BMI and atypical balance score would predict SAD treatment
outcomes (irrespective of treatment type) at post-treatment and at first and second winter
follow-ups. Specifically, we predicted that higher BMI would be a positive prognostic
indicator of outcomes in both treatments. However, our approach explored the empirical
questions of whether BMI and atypical balance emerge as prescriptive factors that
differentially predict: 1) depression outcomes between CBT-SAD and LT at posttreatment and first and second winter follow-ups, and 2) the rate of improvement in
depression scores between CBT-SAD and LT across the six-week treatment period.
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CHAPTER 2: METHOD
Participants
Participants were recruited via newspaper and radio announcements and referrals
from Vermont area health providers. Eligible participants were 18 or older and met the
following inclusion criteria: (a) DSM-IV-TR criteria for major depression, recurrent with
seasonal pattern, (b) SIGH-SAD score of 20 or greater, indicative of a current SAD
episode, and (c) no current antidepressant use or consistent use of the same antidepressant
medication(s) for the past four weeks with no plans to change. Individuals were excluded
for: (a) current treatment with light therapy or psychotherapy for depression; (b) prior LT
or CBT-SAD; (c) diagnosis of psychosis, bipolar disorder, substance abuse/dependence,
or other disorder requiring immediate treatment; (d) current and serious suicidal intent;
(e) hypothyroidism, as indicated by a medical work-up; and (f) planned travel for a week
or more through the end of March.
Treatments
Light Therapy (LT). Participants randomized to LT first attended an
instructional session involving demonstrated assembly, positioning, and use of the light
box, a 23x15½x3¼-in. SunRay that emits 10,000 lux of cool-white fluorescent
ultraviolet-filtered light. The session included a review of the treatment rationale and
possible side effects. The starting dose for all participants was 30 minutes upon waking,
and after treatment week 1, treatment dose was titrated to maximize response and reduce
side effects. If the treatment dose produced an insufficient response – defined as less than
30% reduction in SIGH-SAD score in week 1, less than 50% reduction in week 2, or nonremission on the SIGH-SAD at week 3 and beyond – LT duration was increased by 15-
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minutes weekly to a maximum of two hours per day. If significant side effects were
reported, LT duration was decreased by 15-minutes weekly to no less than 30 minutes per
day. In the case of severe side effects (e.g., migraines), participants took a 1-day hiatus
from LT, and resumed treatment the following day at 50% of the prescribed duration with
subsequent increases until side effects were tolerable. For reports of early morning
waking and/or sleepiness in the early evening, morning LT dose was reduced and/or a
daily light session was added in the evening, starting with 10 minutes and increased as
needed. Side effects were monitored using weekly self-report logs. Each week, the
principal investigator and a chronobiological psychiatrist met to review each light therapy
subject’s file and adjust LT dose. Recommended clinical adjustments to dosage were
relayed to LT participants within 24 hours. Participants were encouraged to continue LT
on their own post the six weeks of monitored treatment until spontaneous springtime
remission. Light boxes were collected from the participants in May. Access to light boxes
was offered again the following fall.
Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD).
CBT-SAD (Rohan, 2008) was adapted from traditional CBT for depression and
specifically addresses behaviors and cognitions related to depression in the winter season.
CBT-SAD utilizes behavioral activation and cognitive restructuring. Behavioral
activation, which involves the identification, scheduling, and completion of pleasant
events, is used to target wintertime anhedonia. Cognitive restructuring consists of
identifying and reframing negative automatic thoughts, including thoughts about the
winter season, lack of light, and inclement weather, and core beliefs. The program
concludes with the creation of a personalized relapse-prevention plan, in which
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participants are taught to implement CBT skills upon their first signs of negative
thoughts, feelings, and behaviors related to the winter season to prevent recurrence.
Although CBT is typically delivered weekly as 20 1-hour long sessions over 16 weeks,
CBT-SAD is condensed into 12 1.5-hour sessions delivered twice weekly to
accommodate the winter season. Sessions were facilitated by one of three licensed
doctoral-level clinical psychologists, with a clinical psychology graduate student cofacilitator. Group sized ranged between four to eight participants, and sessions were
audio-recorded to assess treatment fidelity.
Measures
Body Mass Index (BMI). At pre-treatment, body weight was measured with a
calibrated scale to the nearest 0.01 kilogram, and height was measured to the nearest 0.01
centimeter. A trained study nurse, who also documented medical comorbidities (e.g.,
hypertension, diabetes, etc.), collected BMI data. BMI was analyzed primarily as a
continuous variable. When analyzed as a categorical variable, BMI was categorized
according to Centers for Disease Control and Prevention (2019) guidelines as follows:
BMI < 18.5 is underweight, 18.5 < BMI < 24.9 is normal/healthy weight, 25.0 < BMI <
29.9 is overweight, and BMI > 30.0 is obese.
SIGH-SAD. Depressive symptoms were assessed with the 29-item SIGH-SAD
(Williams et al. 1992). The current study uses SIGH-SADs from pre-treatment to obtain
the atypical balance predictor and SIGH-SADs from post-treatment and at first and
second winter follow-up as outcomes. The measure includes two subscales – the 21-item
Hamilton Rating Scale for Depression (HAM-D; Williams et al., 1998), and an 8-item
subscale assessing atypical symptoms. Higher scores indicate more depressive severity.
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Training for SIGH-SAD administration included listening to, rating, and discussing item
scores for several audiotaped SIGH-SADs with the group of raters, and administering a
mock SIGH-SAD with the study principal investigator. Interviews were audio-recorded
and re-rated by a second blind rater; inter-rater reliability was high at each time point
(Rohan, Rough et al., 2016).
Atypical balance was calculated with the SIGH-SAD as 8-item atypical score /
total SIGH-SAD score x 100 (Terman et al., 1996). Atypical symptoms captured on the
SIGH-SAD include social withdrawal, weight gain, appetite increase, increased eating,
carbohydrate craving and eating, hypersomnia, fatigue, and mood and/or energy slumps
in the afternoon and/or evening.
Remission was defined as either: 1) a > 50% reduction in total SIGH-SAD score
relative to pre-treatment with a HAM-D score <7 and an atypical score <7, or 2) HAM-D
score <2 and an atypical score <10 (Terman et al., 1990). Recurrence was assessed at first
and second winter follow-up and was defined as a total SIGH-SAD score of > 20 with the
HAM-D score >10 and the atypical scale score >5 (Terman et al., 1990).
Data Analytic Plan
The project is a secondary data analysis of a randomized clinical trial on
treatment for SAD conducted at the University of Vermont in the Mood and Seasonality
Laboratory. The study was approved by the University’s Institutional Review Board.
Study procedures are published elsewhere (Rohan et al., 2013).
Analyses were conducted in SPSS 24 for Macintosh. Analysis of variance
(ANOVA) tested for baseline differences between CBT-SAD and LT groups in BMI and
atypical balance score. Correlations were run between BMI, atypical balance, and SIGH-
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SAD score at pre-treatment. We used a Chi-Square to test whether the proportions of
participants in the three BMI categories (normal weight, overweight, and obese) differed
between CBT-SAD and LT.
To address Aim 1, hierarchical multiple regression analyses were used to test the
main effect of each predictor (pre-treatment BMI and atypical balance), treatment type
(CBT-SAD or LT), and their interaction in predicting continuous SIGH-SAD depression
scores at post-treatment, first winter follow-up, and second winter follow-up. Given that
remission status (assessed at post-treatment and first and second winter follow-ups) and
recurrence status (assessed at first and second winter follow-ups) are dichotomous
outcomes, logistic regression analyses were used to test the main effects of BMI and
atypical balance, treatment type (CBT-SAD or LT), and the interaction in predicting
SIGH-SAD remission and recurrence.
Regression analyses utilized all available data. Missing data was minimal, as
174/177 (98.3%) participants provided post-treatment data (Rohan et al. 2015), and
170/177 (96.0%) and 169/177 (95.5%) participants provided data at first and second
winter follow-up, respectively (Rohan, Meyerhoff et al., 2016). As such, missing data
was handled via listwise deletion.
We used the procedures outlined by Kraemer and colleagues (2002) to test pretreatment BMI and atypical balance as predictors and moderators of treatment outcome.
Both pre-treatment BMI and atypical balance were centered on the grand mean before
calculating subsequent interaction terms (Cohen, Cohen, West & Aiken, 2003).
Significant interactions were plotted using a simple slopes analysis and investigated using
the Johnson-Neyman technique to determine regions of statistical significance (p <.05).
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Prognostic indicators (i.e., non-specific predictors of treatment outcome) are
defined as variables with significant main effects. Prescriptive factors (i.e., moderators of
treatment outcome) are variables with significant treatment by predictor interactions. In
all models, we utilized dummy coded treatment variables (CBT-SAD = 1, LT = 0).
Models for testing the moderators included first-order terms and interaction terms to
examine the effect of pre-treatment BMI and atypical balance on treatment outcome in
CBT-SAD vs. LT. Parameter estimates for the treatment effects indicate differences
between CBT-SAD and LT, parameter estimates for the interaction terms indicate
treatment group differences in the effect of pre-treatment BMI or atypical balance on
treatment outcome.
Pre-treatment depression severity (as measured by the SIGH-SAD) was included
as a covariate. Antidepressant medication status, presence of a physical comorbidity,
presence of a mental health comorbidity, gender, education, marital status, and
race/ethnicity (White/non-Hispanic vs. all others) were investigated as potential
covariates. Variables that were significantly correlated with a depression outcome at posttreatment, first winter, or second winter follow-up, were included as covariates in the
relevant analysis of that outcome at that timepoint.
To address Aim 2, growth curve modeling was used to examine the impact of the
BMI and atypical balance on rate of improvement in depression symptoms from baseline
over the six-week treatment period. The intercept will represent individual pre-treatment
depression symptom scores. The main effect of BMI represents the relationship between
BMI and pre-treatment SIGH-SAD depression symptomatology. In these mixed effects
models, the slope represents the rate of change in depression symptoms over the six-week
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treatment period after pre-treatment (intercept). The dependent variables are seven SIGHSADs administered weekly. Here, an association between BMI and the slope would
reflect a relationship between BMI and the rate of improvement in depression symptoms
over the six-week treatment period. We also examined the interactions between BMI,
treatment group, and time. As such, a 3-way interaction between BMI, treatment group,
and time would signify that the effect of BMI on the rate of improvement in depression
symptoms differs by treatment group. Similar modeling was used to assess the impact of
baseline atypical balance on rate of improvement in depression symptoms from baseline
over the six-week treatment period.
Depression scores at pre-treatment and over the six-week treatment period were
first modeled as a random effect of time with a random intercept to allow individual
growth curves for each person. Next, the main effects (BMI and treatment group),
followed by the interactions between BMI, treatment group, and slope were entered into
the model. Plotted simple slopes were used to examine significant interactions.
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CHAPTER 3: RESULTS
Descriptive Findings
Table 1 presents predictor variable means and baseline medical comorbidities by
treatment group. There were no significant differences by treatment group in baseline
BMI, baseline atypical balance, or medical comorbidities. Study participant baseline
characteristics and descriptives are published elsewhere (Rohan et al., 2015). Medical
comorbidity and BMI data were collected on 153/177 participants. The remaining 24
participants were part of a pilot study conducted prior to implementation of the medical
screening visit.
The average BMI across study participants was in the overweight range (M =
27.6, SD = 5.66). Average baseline atypical balance was 40.8%, meaning that atypical
symptoms comprised approximately 41 percent of a participant’s pre-treatment SIGHSAD score, on average. Nearly two-thirds (62.1%) of participants had a medical
comorbidity. The most common physical issues included cardiovascular conditions
(23.5%), gastrointestinal issues (14.5%), and asthma/respiratory conditions (14.5%).
Correlations between predictor variables, possible covariates (e.g., gender, marital
status, education level, race, antidepressant use) and depression outcome measures are
presented in Table 2. Of note, pre-treatment depression scores were significantly
correlated with nearly all depression outcomes; as such, we adjusted for baseline
depression score in all regression analyses. Neither BMI nor baseline atypical balance
were significantly correlated with depression outcomes at any time point. Presence of a
physical comorbidity at baseline was significantly associated with post-treatment SIGH-
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SAD score, r(147) = .17, p = .040. The presence of a mental health comorbidity was
correlated with Winter 2 SIGH-SAD depression recurrence, r(166) = .20, p = .010.
Regression diagnostics revealed non-normal distribution of BMI across the
sample. We ran analyses using the appropriate transformation of BMI (log BMI), but
found that this transformation did not change the general pattern of findings. As such, for
ease of understanding, results are presented from analyses conducted with BMI data in
their original (raw score) form.
BMI Predicting SIGH-SAD Scores
The results of hierarchical regression models with BMI predicting SIGH-SAD
scores at post-treatment, Winter 1, and Winter 2 are presented in Table 3. The overall
model with BMI predicting post-treatment SIGH-SAD score was significant throughout
all regression steps in the model, F[5, 143] = 3.97, p = .002. The variables included in
Step 1 of the model, pre-treatment SIGH-SAD score and presence of a medical
comorbidity, significantly predicted post-treatment SIGH-SAD score, and together
accounted for 11% of the variance in the outcome, ∆R2 = .11, ∆F = 9.47, p < .001.
Neither the variables added in step 2 (BMI and treatment group) nor the BMI x treatment
group interaction term added in Step 3 were significantly associated with post-treatment
SIGH-SAD score.
The overall model with BMI predicting Winter 1 SIGH-SAD score was
statistically significant at Step 1, F[1, 169] = 12.05, p < .001, and remained significant
through subsequent steps in the model. Pre-treatment SIGH-SAD score, included in Step
1, explained 7% of the variance in Winter 1 SIGH-SAD score, ∆R2 = .067, ∆F = 12.05, p
< .001. None of the variables included in Step 2, BMI and treatment group, nor the BMI
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x treatment group interaction term in Step 3, were significantly associated with Winter 1
SIGH-SAD score.
The overall model predicting Winter 2 SIGH-SAD score, which included pretreatment SIGH-SAD score, race, BMI, treatment group, and the BMI x treatment group
interaction was statistically significant, F[5, 140] = 3.52, p = .005. Treatment group,
added in Step 2, significantly predicted the outcome such that Winter 2 SIGH-SAD
scores for those who received CBT-SAD were, on average, 3 points lower than that of
those who received LT. The addition of the BMI x treatment group interaction at Step 3
did not significantly predict Winter 2 SIGH-SAD scores.
Baseline Atypical Balance Predicting SIGH-SAD Scores
Table 3 presents the results of hierarchal regression models with baseline atypical
balance predicting SIGH-SAD scores at post-treatment, Winter 1, and Winter 2. The
overall model predicting post-treatment SIGH-SAD score was statistically significant at
Step 1, F[2, 146] = 9.47, p <.001, and remained significant throughout additional steps in
the model. In Step 1, pre-treatment SIGH-SAD score and presence of a medical
comorbidity significantly predicted post-treatment SIGH-SAD score and together
explained 12% of the variance in post-treatment SIGH-SAD score, ∆R2 = .115, ∆F =
9.47, p <.001. In Step 2, neither pre-treatment atypical balance nor treatment group
predicted post-treatment SIGH-SAD score. Similarly, the pre-treatment typical balance x
treatment group interaction term included in Step 3 was not statistically significant.
The final model predicting Winter 1 SIGH-SAD score included pre-treatment
SIGH-SAD score, baseline atypical balance, treatment group, and the baseline atypical
balance x treatment group interaction term and was statistically significant, F[4, 164] =
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5.03, p < .001. While the addition of baseline atypical balance at Step 2 significantly
predicted Winter 1 SIGH-SAD score, treatment group did not. The pre-treatment atypical
balance x treatment group interaction term was not statistically significant.
The model predicting Winter 2 SIGH-SAD score was statistically significant at
Step 1 F[2, 162] = 4.46, p < .001, and remained significant throughout all subsequent
steps. The addition of baseline atypical balance and treatment group at Step 2 explained
an additional 4% of the variance in the model after accounting for pre-treatment SIGHSAD score and race at Step 1, ∆R2 = .045, ∆F = 4.043, p = .019. The pre-treatment
atypical balance x treatment group interaction term added at Step 3 did not significantly
predict Winter 2 SIGH-SAD score.
BMI Predicting SIGH-SAD Remission
The overall model predicting SIGH-SAD derpression remission at post-treatment,
which included pre-treatment SIGH-SAD score (Step 1), BMI and treatment group (Step
2), and the BMI x treatment group interaction term (Step 3), was not statistically
significant, Likelihood ratio χ2(4) = 3.51, p = .061, Pseudo R2 = .017.
The overall model predicting Winter 1 SIGH-SAD remission status, which
included pre-treatment SIGH-SAD score at Step 1, BMI and treatment group at Step 2,
and the BMI x treatment group interaction at Step 3, did not significantly predict Winter
1 SIGH-SAD depression remission, Likelihood ratio χ2(4) = 3.79, p = .43, Pseudo R2 =
.019.
The overall model predicting Winter 2 SIGH-SAD depression remission was
statistically significant, Likelihood ratio χ2(4) = 10.02, p = .040, Pseudo R2 = .057. We
observed a significnat effect of BMI on Winter 2 depression remission, OR = 1.12, Z =
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2.16, p = .031. Further, findings from Step 3 revealed a statistically significant BMI x
treatment group interaction term, OR = .855, Z = -2.14, p = .032. A decomposition of this
interaction term (see Figure 1), followed by further probing using the Johnson-Neyman
technique, revealed that the probability of depression remission was higher with CBTSAD than LT for those with a BMI of 26.1 or lower. There was no significant difference
in depression remission between CBT-SAD and LT for individuals with BMI greater than
26.1.
Baseline Atypical Balance Predicting SIGH-SAD Remission
The overall model predicting SIGH-SAD remission at post-treatment, which
included pre-treatment SIGH-SAD score (Step 1), pre-treatment atypical balance and
treatment group (Step 2), and the pre-treatment atypical balance x treatment group
interaction term (Step 3), did not significantly predict SIGH-SAD depression remission at
post-treatment, Likelihood ratio χ2(4) = 4.45, p = .349, Pseudo R2 = .019.
The final model predicting SIGH-SAD depression remission at Winter 1 incldued
pre-treatment SIGH-SAD score (Step 1), pret-treatment atypical balance and treatment
group (Step 2), and the pre-treatment atypical balance x treatment group interaction term
(Step 3), and was also not statistically significant, Likelihood ratio χ2(4) = 9.20, p = .056,
Pseudo R2 = .041.
The overall model predicting Winter 2 SIGH-SAD depression remission was
statistically significant, Likelihood ratio χ2(4) = 13.22, p = .010, Pseudo R2 = .066. At
Step 3, pre-treatment atypical balance, OR = 1.08, Z =2.52, p = .012, and the pretreatment atypical balance x treatment group interaction term, OR = .90, Z = -2.70, p =
.007, significantly predicted Winter 2 SIGH-SAD depression remission. Decomposing
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this interaction (Figure 2) and probing it using the Johnson-Neyman procedure revealed
that the probability of depression remission at Winter 2 was higher with CBT-SAD than
LT for those with pre-treatment atypical balance of 40.3 percent or lower. There was no
significant difference in the probability of depression remission at Winter 2 between
CBT-SAD and LT for individuals with pre-treatment atypical balance greater than 40.3
percent.
BMI Predicting SIGH-SAD Depression Recurrence
The binary logistic regression predicting Winter 1 SIGH-SAD depression
recurrence was statistically significant, Likelihood ratio χ2(4) = 12.03, p = .017, Pseudo
R2 = .071, however, pre-treatment SIGH-SAD score was the only statistically significant
predictor, OR = 1.16, Z = 3.00, p = .003.
Similarly, the overall model predicting Winter 2 SIGH-SAD depression
recurrence was statistically significant, Likelihood ratio χ2(5) = 18.77, p = .002, Pseudo
R2 = .096. Although treatment group, OR = .44, Z = -2.23, p = .026, emerged as a
significant predictor of Winter 2 SIGH-SAD depression recurrence, consistent with the
primary efficacy results showing CBT-SAD’s superiority to LT (Rohan et al., 2016),
neither BMI, OR = .96, Z = -.85, p = .396, nor the BMI x treatment group interaction
term, OR = 1.03, Z = .53, p = .598, was statistically significant.
Baseline Atypical Balance Predicting SIGH-SAD Depression Recurrence
The final model predicting Winter 1 SIGH-SAD depression recurrence was
statistically significant, Likelihood ratio χ2(4) = 11.59, p = .021, Pseudo R2 = .059, and
pre-treatment SIGH-SAD score, OR = 1.10, Z = 2.88, p = .004, was the only significant
predictor.
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Further, the final model predicting SIGH-SAD depression recurrence at Winter 2
was statistically significant, Likelihood ratio χ2(4) = 14.44, p = .006, Pseudo R2 = .065;
while pre-treatment SIGH-SAD score, OR = 1.09, Z = 2.64, p = .008, and treatment
group, OR = .38, Z = -2.78, p = .005, were significant predictors in this model, pretreatment atypical balance, OR = 1.00, Z = .21, p = .835, and the pre-treatment atypical
balance x treatment group interaction, OR = 1.01, Z = -.43, p = .665, were not.
Sensitivity Analyses: BMI and Baseline Atypical Balance as Predictors of
Depression Treatment Outcomes after Adjusting for Each Other
Additional analyses were also conducted to determine if the significant findings
persisted after controlling for BMI and atypical balance in their respective models. To
remain parsimonious, these analyses were only run for models with an observed
significant predictor x treatment group interactive effect.
The overall model examining BMI as a predictor of Winter 2 SIGH-SAD
remission after adjusting for pre-treatment SIGH-SAD score and atypical balance was not
statistically significant, Likelihood ratio χ2(5) = 10.64, p = .059, Pseudo R2 = .061.
The overall model with baseline atypical balance as a predictor of Winter 2
SIGH-SAD remission after adjusting for pre-treatment SIGH-SAD score and BMI was
significant, Likelihood ratio χ2(5) = 14.30, p = .014, Pseudo R2 = .082. Baseline atypical
balance maintained a significant predictive effect on the outcome, OR = 1.08, Z = 2.51, p
= .012. Further, the baseline atypical balance x treatment group interaction also remained
significant, OR = .892, Z = -2.77, p = .006. The direction of the interactive effect was
consistent with the direction seen in the model that did not adjust for BMI.
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Sensitivity Analyses: Categorical BMI as a Predictor of Depression Remission at
Winter 2 Followup
Analyses were also conducted to determine whether the significant effects of BMI
as a predictor of depression remission at second winter followup were still observed with
BMI entered as a categorical variable. Categorical BMI (with normal weight as the
reference group) did not significantly predict depression remission at second winter
followup, Likelihood ratio χ2(6) = 9.20, p = .16, Pseudo R2 = .05.
Aim 2 Findings
Linear mixed models (LMM) investigating the main effects of between-subjects
factors, within-subjects factors, and their interactions on SIGH-SAD score at posttreatment were examined. The final models included the intercept, time, predictor,
treatment group, time x treatment group, time x predictor, and time x predictor x
treatment group, in which the predictor was either BMI or atypical balance at pretreatment. After fitting the models with multiple covariance structures, using unstructured
covariance structure among random effects provided the best model fit as measured by
the AIC and BIC fit statistics, in which lower numbers denote better fit. For instance, fit
statistics were better with the unstructured covariance structure (AIC = 6314.3, BIC =
6333.9) than diagonal covariance structure (AIC = 6322.3, BIC = 6371.0). These
analyses are reported in Table 6.
Predicting Post-treatment SIGH-SAD Scores Using Linear Mixed Modeling
In the BMI model, we observed a main effect of time (slope) such that
participants reported a decrease (negative slope) in SIGH-SAD score across repeated
measurements, F(1, 145.3) = 772.85, p < .001. There were no significant main effects for
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BMI and treatment group, and no significant interactive effects for time x treatment
group or time x BMI. A significant three-way time x treatment group x BMI interaction,
F(1, 141.8) = 4.95, p = .028, suggested that SIGH-SAD scores at each week varied by
treatment group and BMI.
The interaction was investigated by graphing the marginal effects of BMI on the
rate of change of SIGH-SAD scores over the six weeks of treatment by treatment group
(Figure 3). Plotting the interaction revealed a negative BMI x time interaction for light
therapy such that as BMI increases, the rate of change in SIGH-SAD score decreases.
However, there was a positive association between BMI and time for CBT-SAD, such
that as pre-treatment BMI increases, the rate of change in SIGH-SAD scores increases.
In the model examining baseline atypical balance as a predictor of SIGH-SAD
scores, we observed a main effect of time (slope) in that SIGH-SAD scores decreased
approximately 2.5 points per week across repeated measurements, F(1, 169.1) = 800.5, p
< .001. We observed no other significant main effects or interactive effects.
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CHAPTER 4: DISCUSSION
To our knowledge, this is the first study to investigate BMI and atypical balance
at baseline as prescriptive predictors of different SAD treatment outcomes at posttreatment and at follow-ups one and two winters later. BMI was a prescriptive predictor
of the probability of depression remission at Winter 2, such that the probability of
remission was significantly higher with CBT-SAD than LT at BMI < 26.1. Furthermore,
pre-treatment atypical balance was a prescriptive predictor of Winter 2 depression
remission, whereby the probability of remission was significantly higher with CBT-SAD
than LT when atypical balance score was < 40.3 at pre-treatment.
Of note, all three of these significant findings were prescriptive of more
remissions in CBT-SAD than in LT at or below the cutpoint, but were not prescriptive of
more remissions in LT than in CBT-SAD above the cutpoint. This is evident in Figures 1
and 2, illustrating the magnitude of the difference between CBT-SAD and LT is much
larger at one standard deviation below the mean on the predictor, where the difference
favors CBT-SAD, than it is at one standard deviation above the mean, where the
difference favors LT. If the goal is remission in future winters, these results have the
potential to inform treatment algorithms for recommending CBT-SAD over LT for
patients with SAD who are at or below these values. However, the probability of
remission for patients with SAD who are above these mean values did not differ
depending on whether the initial treatment was CBT-SAD or LT, offering no guidance to
the clinician in selecting one treatment over the other. Therefore, these results inform
personalized medicine only for patients with SAD at or below these mean values.
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The overall pattern of results differs from the Dimitrova et al. (2017) study, which
found higher atypical balance and BMI at pre-treatment predicted a greater decrease in
depression scores after LT. We observed a significant advantage of CBT-SAD over LT
for SAD patients with relatively lower BMI and atypical balance, but no significant
advantage of LT over CBT-SAD for SAD patients with relatively higher BMI and
atypical balance. In addition, our pattern of significant findings was observed at winter
follow-ups (not at post-treatment) and on the outcome of depression remission (rather
than continuous depression scores). The current study has several methodological
improvements over Dimitrova et al. (2017), including a comparator treatment for LT (i.e.,
CBT-SAD), a larger sample size, and the longitudinal follow-up interval spanning two
winters beyond treatment endpoint.
Our significant prescriptive findings are concentrated on the dichotomous
outcome of depression remission. Remission is the accepted desired clinical endpoint for
depression treatment, defined as a state in which there are minimal or no depression
symptoms present with a return to normative psychosocial and occupational function
(Zajacka, 2003). Depression remission is the desired clinical treatment outcome because
research demonstrates that failure to achieve remission is associated with greater
likelihood of depression relapse or recurrence (Lovieno et al., 2010), more severe
functional impairment, and poorer long-term outcomes (Olchanski et al., 2013). Given
that remission is an important benchmark of treatment effectiveness, our finding that
relatively lower BMI and atypical balance prescriptively predicted lower risk of
remission following CBT-SAD relative to LT is clinically useful.
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We also examined baseline BMI and atypical balance as prescriptive predictors of
the average weekly rate (i.e., slope) of change in SIGH-SAD score across the six-week
treatment period. This analysis was largely exploratory, as prior work has not examined
these predictors in relation to rate of depression change during treatment. We uncovered a
significant interaction between time, BMI, and treatment group, indicating the rate of
change in SIGH-SAD scores was slower in LT and faster in CBT-SAD as BMI increased.
Based on Dimitrova et al. (2017), we speculated that perhaps LT would be associated
with a faster rate of depression change than CBT-SAD as BMI increased—the opposite
of what was observed here. In considering this short-term advantage of higher BMI in
CBT-SAD (i.e., for greater rate of depression change during the six weeks of treatment)
against the long-term advantage of lower BMI in CBT-SAD (i.e., for greater likelihood of
remission two winters later), we argue the latter is more important, particularly because
BMI was not a prescriptive predictor of post-treatment depression scores.
One framework that may be useful for understanding these results is the “seasonal
thrifty phenotype” hypothesis (Levitan et al. 2006), which purports that due to an early
gene-environment interaction, individuals make predictions about seasonal scarcity of
food resources, resulting in increased risk of obesity with SAD. According to the
hypothesis, the gene-environment interaction occurs via in utero signals that involve
melatonin, which readily crosses the placenta and can provide photoperiodic information
that can then impact rhythms related to seasonality and the circadian clock (Levitan et al.
2006). The core features of this phenotype include seasonal cravings, increased food
intake, reduced activity, marked weight gain, and hypersomnia in preparation for
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predictable seasonal famine, but currently maladaptive in environments with an
abundance of food (Levitan et al., 2006).
It may be the case that the two treatments compared in this study, CBT-SAD and
LT, target different etiologic components of SAD onset. Perhaps CBT-SAD does not
target individuals with SAD who fit the seasonal thrifty phenotype, who would be
expected to have relatively higher BMIs and atypical symptoms. The Dual Vulnerability
Model (Young et al. 2008) states that separate but interconnected biological and
psychological processes are involved in the development and maintenance of SAD
symptoms. The physiological vulnerability to environmental changes (e.g., shortened
photoperiod) leads to vegetative symptoms (e.g., increased appetite, hypersomnia). Then,
due to a psychological vulnerability to the experience of vegetative symptoms, SAD
symptoms related to mood and cognition ensue, such as sadness and guilt. It is possible
that CBT-SAD and LT target different points of vulnerability in this model. While LT
targets the biological vulnerability by artificially lengthening photoperiod, CBT-SAD
impacts the psychological vulnerability by improving coping with seasonal changes.
Thus, it could be that individuals with lower BMI and lower atypical balance show
increased likelihood of remission at follow-up with CBT than LT because CBT targets
the factors at which they are most vulnerable (i.e., psychologically).
The predictive effects of BMI and atypical balance observed in this study could
be explained by dysregulation in immunological or metabolic functioning. Specifically,
meta-analyses suggest levels of specific inflammatory markers, including C-reactive
protein (CRF), tumor necrosis factor (TNF), and interleukin-6 (IL-6), are higher in
depressed individuals than their non-depressed counterparts (Dowlati et al., 2010;
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Howren et al., 2009). Moreover, this effect is substantially attenuated after controlling for
BMI (Howren et al. 2009), suggesting that weight may be an important factor in the
relationship between depression and increased inflammatory response. In their recent
work, Kappelmann et al. (2020) investigated the association between inflammatory
markers, metabolic dysregulation, and specific depression symptoms using genetic
correlation and 2-sample mendelian randomization. Their work found positive
associations between IL-6 activity and suicidality, and that higher BMI, but not
inflammatory markers, was associated with anhedonia, fatigue, appetite change, and
feelings of inadequacy. Together, these results suggest that immune and metabolic factors
may represent separate symptom-specific pathways that increase risk for depression.
Rudolf and colleagues (2014) found levels of IL-6 were higher in individuals with
atypical depression, but not in those with typical depression. Further, those with atypical
depression had significantly higher BMIs, and increased CRP levels compared to their
counterparts with typical depression.
The relationship between immune functioning and depression may be especially
important to consider with SAD, as there is a preponderance of both human and nonhuman animal studies that suggest seasonality impacts immune function. In non-human
animals, immune function is elevated during the shortened photoperiods of the winter
season in response to energetic stress, which involves changes that alter the body’s
energetic state or demand, such as lowered food availability and colder temperatures
(Harrell et al., 2016, Song et al., 2015;). In humans, more inflammatory cells (e.g.,
macrophages) and proinflammatory cytokines (e.g., IL-6), are present in the winter as
compared to the summer (Kulwein & Irwin 2001; Maes et al., 1994; Song et al., 2015).
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Given the relationship between seasonality and immune response, it is useful to
examine how immune response changes with SAD treatment. Investigation of the
relationship between immune functioning and SAD treatment outcomes is limited to LT
and shows mixed results (Avissar et al. 1999; Lue et al. 2001, Song et al., 2015). As such,
future research should examine immune functioning as a potential mechanism of the
relationship between BMI (and atypical balance) and SAD treatment outcomes and
whether this varies by treatment type (e.g., LT vs. CBT-SAD vs. medication).
Given that prior research demonstrates an association between BMI and some
atypical symptoms of depression (Lamers et al. 2017; Lojko et al., 2015), one promising
avenue for future research is to elucidate the underlying common biological mechanisms
common to both factors and explore how they may influence depression treatment
outcomes. For example, Akram and colleagues (2020) investigated the relationship
between adiponectin – a hormone important for insulin and anti-inflammatory action –
and SAD symptoms among an Old Older Amish sample. They found that participants
with syndromal or subsyndromal SAD had significantly lower adiponectin plasma levels
that those without SAD symptoms (Akram, 2020), suggesting that this hormone may be
an important target for treatment. As such future research can examine how this hormone
changes in response to treatment for SAD and major depressive disorder more broadly.
While there is much utility in examining the underlying biological mechanisms
that may explain the observed relationship between BMI, atypical balance, and
depression treatment outcomes, future research should also take a broader, more
sociological perspective. Depression and obesity are highly comorbid (Levitan et al.,
2012; Luppino et al., 2010), and both are stigmatized (Ebneter et al. 2013; Mooney et al.,
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2016). Luck-Skiroriki et al. (2018) conducted a telephone-based study in which
participants were presented with vignettes of women with depression, obesity, or both,
and followed by semantic differentials (i.e., the Depression Stigma Scale and the
Fatphobia Scale) to capture stigma towards these conditions. They found that the cooccurrence of obesity and depression was associated with increased levels of stigma as
compared to the occurrence of obesity or depression independently. As such, future
research should also examine how the stigma surrounding obesity and depression may
impact treatment outcomes.
Several limitations to this work must be acknowledged. First, the SIGH-SAD is
an interview that relies on self-report to capture the intensity and frequency of depression
symptoms. Although the accepted measure of SAD symptom severity, the items that
comprise the atypical subscale (e.g., hypersomnia, increased eating, fatigue) capture the
perception of these constructs, which may differ from the data captured by means that
track behavioral or physiological data. A second limitation surrounds the use of BMI as a
moderator. Other metrics, such as waist-to-height ratio (Ashwell et al. 2012), may be
more accurate/useful markers of metabolic dysregulation, as BMI does not account for
muscle mass or distribution of adipose tissue. Finally, study data were collected in the
state of Vermont with a predominantly older, white population, which may impact
generalizability of the findings. Future research should involve multi-site data collection
with individuals from various racial and ethnic backgrounds to improve generalizability.
Despite these shortcomings, this paper makes an important contribution to the literature
on how different factors impact depression treatment outcomes.
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Table 1: Descrptive statistics on predictors variables and baseline medical comorbidities
Total

BMI (N= 153)
Atypical balance (N=
177)

Mean

SD

27.56
40.8

5.66
10.07

Total
(N
=153)
No.

%

Treatment
Group
CBT-SAD
M (SD)
27.8 (5.94)
41.7 (10.09)

LT
M (SD)
27.3 (5.40)
39.9 (10.02)

CBT (N = 76)

LT (N = 77)

No. (%)

No. (%)

t

p

-.603
-1.17

.547
.244

Chisquare
2.31

p

BMI (categorized)
.314
Normal range
56
36.6
28 (36.8)
28 (36.4)
Overweight
54
35.3
23 (30.3)
31 (40.3)
Obese
43
28.1
25 (32.9)
18 (23.4)
Any Comorbidity
95
62.1
52 (68.4)
43 (55.8)
2.57
.109
Asthma/respiratory
16
10.5
11 (14.5)
5 (6.5)
2.60
.107
Bones/joints/muscles
16
10.5
8 (10.5)
8 (10.4)
.001
.978
Cardiovascular
36
23.5
21 (27.6)
15 (19.5)
1.41
.235
Diabetes
6
3.9
5 (6.6)
1 (1.3)
2.83
.092
Gastrointestinal
26
17.0
11 (14.5)
15 (19.5)
.680
.410
Genitourinary
8
5.2
5 (6.6)
3 (3.9)
.556
.456
Head injury
2
1.3
1 (1.3)
1 (1.3)
.000
.993
Headache/migraine
9
5.9
5 (6.6)
4 (5.2)
.132
.716
Nervous System
16
10.5
9 (11.8)
7 (9.1)
.309
.578
Cancer History
9
5.9
3 (4.0)
6 (7.8)
1.02
.312
Skin
10
6.5
6 (7.9)
4 (5.2)
.456
.499
Sleep
6
3.9
4 (5.3)
2 (2.6)
.721
.396
Thyroid function
18
11.8
10 (13.2)
8 (10.4)
.282
.595
Other
10
6.5
7 (9.2)
3 (3.9)
1.77
.184
Notes.
BMI = body mass index; CBT-SAD = Cognitive Behavioral Therapy for Seasonal Affective Disorder;
LT = Light therapy. Note that N for Medical comorbidities is smaller than overall N.
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Table 2: Bivariate correlations between predictor and depression outcome measures
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1. Sex
2. Age
3. Race
4. Antidepressant
Use
5. Education
6. Marital Status
7. MH
Comorbidity
8. PH
Comorbidity
9. BMI
10. Atypical
balance
11. Pre-tx SIGHSAD
12. Post-tx SIGHSAD
14. W1 SIGHSAD score
15. W2 SIGHSAD score
16. Post-tx SIGHSAD remission
17. W1 SIGHSAD remission
18. W2 SIGHSAD remission
19. W1 SIGHSAD recurrence
20. W2 SIGHSAD recurrence

1.

2.

3.

4.

5.

6.

7.

---.10
-.05
.01

--.08
.14

--.08

---

-.04
-.02
-.11

.14
-.13
-.15*

.00
.04
-.16*

.01

.31**

-.16*
.09

8.

9.

10.

-.04
-.07
.09

---.12
.10

---.09

---

-.04

.17*

-.03

.07

.10

---

.06
-.09

-.12
.04

.09
.08

.00
.07

-.09
-.13

.19*
.02

.03

.00

-.03

.08

-.01

-.06

.03

.05

-.06

.06

-.04

-.04

.06

-.10

-.02

.05

.13

-.17*

.05

.00

.05

11.

12.

14.

15.

16.

17.

18.

19.

.10
-.16

--.08

---

.17*

.01

.07

.18*

---

.10

.12

.17*

.01

.04

.27**

---

-.09

.00

.11

.11

-.05

-.14

.26**

.27**

---

-.03

.05

.05

.14

.08

-.05

-.06

.18*

.22**

.54**

---

.07

.00

.00

-.12

-.10

-.13

-.11

.04

-.14

-.77**

-.27**

-.25**

--

-.06

.02

.09

.06

.02

-.07

-.15

.01

.12

-.10

-.22**

-.75**

-.44**

.22**

--

-.08

-.11

.07

.01

-.03

.01

-.14

-.16

.07

.06

-.09

-.15*

-.39**

-.74**

.15*

.41**

---

-.04

.03

-.07

-.04

-.08

.07

.03

.09

-.10

-.11

.21**

.16*

.79**

.39**

-.16*

-.46**

-.19*

--

.07

.13

-.12

-.01

.09

-.04

.20*

.07

.00

.05

.19*

.13

.46**

.83**

-.17*

-.36**

-.49**

.38**

2
0.

--

PH = physical health; MH = mental health; Pre-tx = pre-treatment; Post-tx = post-treatment; SIGH-SAD = Structured Interview Guide for the Hamilton
Depression Rating Scale – Seasonal Affective Disorder Version; W1 = first winter followup; W2 = second winter followup
*Correlation is significant at the .05 level (2-tailed).
**Correlation is significant at the .01 level (2-tailed).

Table 3: Regression Analyses Predicting Depression Scores
Outcome:
SIGH-SAD

Post-tx SIGH-SAD

Winter1 SIGH-SAD score

B
S.E. t
p
b
S.E. t
Predictor: BMI
Intercept
10.8 .97
11.06 <.001
15.2
.98
15.57
Pre-tx
.38
.10
3.84
<.001
.46
.13
3.64
SIGH-SAD
CBT-SAD
.47
1.1
.436
.662
-.52
1.4
-.379
vs. LT
Physical
2.2
1.1
1.98
.049
---Comorbidity
Race
-------BMI
-.12 .14
-.874 .383
-.14
.19
-.732
BMI x
.18
.19
.961
.338
.05
.25
.184
txgroup
Predictor: Atypical Balance (AB)
Intercept
10.7 .96
11.09 <.001
15.13 .89
16.94
Pre-tx
.35
.10
3.49
.001
.46
.12
3.92
SIGH-SAD
CBT-SAD
.40
1.08 .37
.715
-.21
1.3
-.160
vs. LT
Physical
2.2
1.13 1.97
.051
---Comorbidity
Race
-------Atypical
-.02 .078 -.208 .835
-.22
.09
-2.49
balance
AB x
.09
.11
.842
.401
.11
.13
.915
txgroup
Notes:
txgroup = treatment group (CBT-SAD vs. LT), AB = atypical balance
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Winter 2 SIGH-SAD score

p

b

S.E.

t

p

<.001
<.001

26.0
.38

4.13
.14

6.29
2.76

<.001
.007

.705

-3.4

1.5

-2.20

.029

--

--

--

--

--

-.465
.855

-1.3
-.28
.25

.72
.20
.29

-1.76
-1.43
.868

.081
.155
.387

<.001
<.001

25.7
.34

3.99
.13

6.46
2.71

<.001
.007

.870

-3.59

1.4

-2.62

.010

--

--

--

--

--

-.014

-1.2
-.19

.69
.09

-1.80
-2.04

.074
.043

.362

.25

.13

1.88

.061

Table 4: Regression Analyses Predicting Depression Remission
Outcome:
SIGH-SAD

Predictor: BMI
Intercept

Post-treatment Remission

Winter 1 remission

b

S.E
.

Z

p

b

S.
E.

Z

p

b

S.E
.

Z

p

-.20

.23

-.84

.402

-.57

.24

-2.34

.019

-1.2

.28

-4.27

-1.86

.063

-.06

.03

-1.65

.098

-.07

.04

-1.78

<.00
1
.075

.350

.728

.09

.34

.27

.790

.56

.38

1.50

.134

-.346
-.701

.729
.483

.05
-.07

.05
.06

1.02
-1.14

.308
.255

.11
-.16

.05
.07

2.16
-2.14

.031
.032

-.56

.572

-.61

.24

-2.56

.011

-1.3

.28

-4.66

Pre-tx SIGH-.06 .03
SAD
CBT-SAD vs.
.12
.34
LT
BMI
-.02 .04
BMI x txgroup
-.04 .06
Predictor: Atypical Balance (AB)
Intercept
-.12 .22
Pre-tx SIGHSAD
CBT-SAD vs.
LT
Atypical
balance
AB x txgroup

Winter 2 remission

-.06

.03

-1.98

.048

-.05

.03

-1.53

.126

-.05

.03

-1.51

<.00
1
.131

.03

.31

.107

.915

.12

.33

.37

.709

.68

.37

1.86

.064

.02

.02

.842

.400

.07

.03

2.56

.010

.07

.03

2.52

.012

-.01

.03

-.269

.788

-.07

.03

-2.05

.041

-.10

.04

-2.70

.007
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Table 5: Regression Analyses Predicting SIGH-SAD Depression Recurrence

Predictor: BMI
Intercept
Pre-tx SIGH-SAD
CBT-SAD vs. LT
Mental health
comorbidity
BMI
BMI x txgroup
Predictor: Atypical balance
Intercept
Pre-tx SIGH-SAD
CBT-SAD vs. LT
Atypical balance
Atypical balance x
txgroup

Winter 1 Recurrence
b
S.E.
Z

p

Winter 2 Recurrence
b
S.E.
Z

p

-1.35
.11
.299
--

.30
.04
.396
--

-4.58
3.00
.753
--

<.001
.003
.451
--

-.42
.074
-.83
1.02

.27
.035
.37
.41

-1.57
2.13
-2.23
2.49

.117
.033
.026
.013

-.05
-.01

.06
.08

-.874
-.145

.382
.885

-.04
.04

.05
.07

-.848
.527

.396
.598

-1.25
.097
.309
-.04
.01

.275
.034
.367
.03
.04

-4.55
2.88
.842
-1.50
.242

<.001
.004
.400
.13
.809

-.097
.085
-.961
.00
.01

.223
.03
.345
.02
.03

-.43
2.64
-2.78
.208
.215

.665
.008
.005
.835
.830
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Table 6: Linear Mixed Models Predicting Depression Post-Treatment Scores

Predictor: BMI
Intercept
Time (Slope)
Treatment Group
BMI
Time (slope) x Treatment Group
Time (slope) x BMI
Time (slope) x Treatment Group x BMI
Predictor: Baseline atypical balance
Intercept
Time (Slope)
Treatment Group
Pre-tx atypical balance
Time (slope) x Treatment Group
Time (slope) x Pre-tx atypical balance
Time (slope) x Treatment Group x Pre-tx atypical balance

35

DV: SIGH-SAD score
β
df
t

p

26.68
-2.48
-.826
.022
-.058
.025
-.064

155
150
151
151
145
168
142

39.55
-19.01
-.875
.264
-.320
1.176
-2.22

<.001
<.001
.383
.792
.749
.241
.028

26.73
-2.48
-1.05
.0723
-.067
-.004
-.003

181
174
177
175
168
191
162

41.82
-19.34
-1.17
1.625
-.375
-.384
-.196

<.001
<.001
.245
.106
.708
.701
.845

Figure 1: Decomposed BMI by Treatment Group Interaction on Probability of Winter 2 SIGH-SAD
Remission
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Figure 2: Decomposed Pre-treatment Atypical Balance by Treatment Group Interaction on Probability of
Winter 2 SIGH-SAD Remission
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Figure 3: Marginal Effects of Centered BMI on Change in SIGH-SAD Score by Treatment Group
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